Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Disc Medicine, Inc.

NASDAQ: IRON · Life Sciences · 6 alerts · CIK 1816736

Disc Medicine, Inc. stories on ALFA USA NewsRead the news →
Share price
$76.59Close, Nov 16
Market cap
$3.49B
Shares outstanding
45.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Disc Medicine, Inc. filings on SEC EDGAR ↗

7:08 AM ET 8-K
Clinical Trial Data

Disc Medicine Clinical Trial Data

Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.

Term
6 months

“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”

Will Savage, M.D., Ph.D., Chief Medical Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.